source
- Novo Nordisk faces investor skepticism at Capital Markets Day as it outlines consumer and obesity growth plansNovo Nordisk held its Capital Markets Day in London, where CEO Mike Doustdar acknowledged the need to reassure a restless investor audience. The company has recently streamlined its brand after a p…
- China aims for 25% of global first-in-class drugs by 2030 under new five-year planChina's government has set an ambitious target to capture at least a quarter of the world’s first‑in‑class drug discoveries by 2030. The goal is part of a five‑year plan released by the National Me…